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Nanogels are nanosized crosslinked polymer networks capable of absorbing large quantities of water.
Specifically, smart nanogels are interesting because of their ability to respond to biomedically relevant
changes like pH, temperature, etc. In the last few decades, hybrid nanogels or composites have been
developed to overcome the ever increasing demand for new materials in this field. In this context, a hybrid
refers to nanogels combined with diﬀerent polymers and/or with nanoparticles such as plasmonic,
magnetic, and carbonaceous nanoparticles, among others. Research activities are focused nowadays on
using multifunctional hybrid nanogels in nanomedicine, not only as drug carriers but also as imaging and
theranostic agents. In this review, we will describe nanogels, particularly in the form of composites or
hybrids applied in nanomedicine.
1. Introduction
Nanogels are nanosized hydrogel particles that combine the
properties of both hydrogels and nanomaterials.1 Like hydrogels,
they show high water content, tunable chemical and physical
structures, good mechanical properties, and biocompatibility.2
The nanoscale mainly provides a large surface area for bio-
conjugation, long time of circulation in blood, and tunable size
from nanometers to micrometers with the possibility of being
actively or passively targeted to the desired site of action, e.g.,
tumor sites.3 The sum of these properties plus the presence
of an interior network for the encapsulation of biomolecules
makes nanogels ideal candidates for their application in nano-
medicine.4,5 Nanomedicine is the application of nanotechnol-
ogies to the medical field as drug delivery systems, imaging and
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sensing agents, theranostic materials, among others. Smart
nanogels have attracted much attention for their application
in medicine due to their capacity to respond to diverse medically
relevant stimuli6 like pH,7 temperature,8–11 ionic force,12 redox
environment,13 etc., by changing their volume, refractive index,
and hydrophilicity–hydrophobicity.14
In recent years, the development of advanced or hybrid
nanogels with multifunctionality and novel properties has been
of interest in many research fields ranging from materials
science to nanomedicine.15,16 Hybrid nanogels can be classified
based on their diﬀerent properties. For the purpose of this review,
we divided the hybrid nanogels into two categories: nanomaterial–
nanogel and polymer–nanogel composites and we use @ in the
nomenclature of the nanomaterial–nanogel composites mean-
ing that the new component is hybridized with the nanogel.
Nanomaterial–nanogel composites have also been synthesized
by incorporation of nanosized materials such as plasmonic,17,18
magnetic,19–21 and carbonaceous nanoparticles,22 like carbon
nanotubes,23,24 graphene,25 and fullerenes.26 These materials
are of great interest in nanomedicine due to their applicability
for imaging,27 guided therapy,19 triggered drug release,28 and
hyperthermia,29 among others. Furthermore, polymer–nanogel
Juan Balach
Dr Juan Balach received his PhD
degree in Chemistry from National
University of Rio Cuarto in 2011
supervised by Prof. Ce´sar Barbero
and was a postdoctoral fellow
(2012) in the Department of
Colloid Chemistry at the Max
Planck Institute of Colloids and
Interfaces, Germany. Since 2013,
he has been a Research Associate
at the Institute for Complex
Materials, Leibniz Institute for
Solid State and Materials Research
(IFW) Dresden, Germany. His
research interests mainly focus on the rational design of advanced
carbon-based materials for electrochemical energy storage applications.
Julian Bergueiro
Dr Julian Bergueiro received
his BS and MS in Chemistry
from the University of Santiago
de Compostela (Spain) in 2007
and 2008, respectively. In 2013
he received his PhD from USC
under the supervision of Prof.
S. Lopez. In 2012 he joined the
group of Prof. R. Riguera to work
on the synthesis and characteriza-
tion of stimuli-response helical poly-
mers and poly(phenylacetylene)s@
gold nano-particle nanocomposites.
He joined Prof. M. Caldero´n
group in 2013 to carry out his postdoctoral research at Freie
Universita¨t Berlin. Recently he was awarded with a Dahlem
International Net-work Postdocs Fellowship to develop gold based
thermoresponsive nanogels as nanocarriers.
Enrico Miceli
Enrico Miceli received the BSc in
Chemistry from the University of
Padova (Italy) in 2007. In 2013
he received the MSc in Chemistry
from the Freie Universita¨t Berlin
(Germany). In 2014 he started his
PhD studies in the research group
of Prof. Marcelo Caldero´n in
collaboration with Prof. Joachim
Dzubiella. He is involved in the
investigation of the interaction
between proteins and thermo-
responsive nanogels. Marcelo Caldero´n
Marcelo Caldero´n is an Assistant
Professor for Macromolecular and
Organic Chemistry at the Depart-
ment of Biology, Chemistry,
and Pharmacy from the Freie
Universita¨t Berlin, Germany. Dr
Caldero´n received his PhD in
organic chemistry in 2007 from
the National University of
Co´rdoba, Argentina, under the
supervision of Prof. Miriam
Strumia. In 2007 he joined the
Research Group of Prof. Rainer
Haag at the Freie Universitat
Berlin for his Postdoctoral work, where he pursued the
development of polymer-drug conjugates for the passive targeted
delivery of drugs, genes, and imaging probes. Dr Caldero´n was the
recipient of the Arthur K. Doolittle Award in 2010 (ACS, Polymer
Materials), the Cesar Milstein Fellowship in 2011 (Ministry of
Science, Technology and Productive Innovation, Argentina), and
the NanoMatFutur Grant for Young Scientists from the German
Ministry of Science in 2012 (BMBF).




























































































This journal is©The Royal Society of Chemistry 2015 Chem. Soc. Rev., 2015, 44, 6161--6186 | 6163
composites include interpenetrated networks (IPNs) and core–
shell particles. The advantage of hybridizing the nanogels
with other polymers and not only copolymerizing them is that
each component maintains its original properties. The core–
shell strategy is especially useful for targeting therapy30 while
the interpenetration allows the development of multiresponsive
nanogels31 and the control of the release profile.32 Several reviews
about synthesis and characterization of nanogels have been
published.4,33–36 In this review, we will focus on the description
of different hybrid nanogels and their application in the nano-
medicine field (Fig. 1). In addition, it is hoped that this review
will promote further design and development of new hybrid
materials as well as deeper studies for shortening the path to
their clinical application.
2. Nanomaterial–nanogel composites
The possibility of combining the properties of organic and
inorganic components in one material widens their applications
in diﬀerent fields like materials science. However, the so-called
hybrid inorganic–organic materials are not physical mixtures
but intimately mixed systems. The resulting properties, such as
nanostructure, degree of organization, etc., not only depend on
their components’ nature but also on the synergy between
the components. These inorganic–organic composites can be
classified according to the nature of the interactions between
the components into (a) class I systems where no covalent bonds
are formed between the organic and inorganic components and
only weak interactions are present such as hydrogen bonding,
van der Waals, or electrostatic forces and (b) class II where strong
chemical bonds such as covalent or Lewis acid–base bonds are
present.37,38 Without any doubt, these new generations of
hybrid materials will open up new possibilities for application
in different areas of nanomedicine such as, for example, optical
sensing,39 on demand drug delivery,40 imaging,41 and hyperthermia
therapy.19
In this section diﬀerent nanomaterial–nanogels and their appli-
cation in nanomedicine will be described, including plasmonic@,
magnetic@, and carbonaceous material@nanogels.
2.1. Plasmonic@nanogels
Photothermal therapy (PTT) and photodynamic therapy (PDT) are
currently the most promising techniques for treating cancer.42
This is because of the possibility of engineering devices in
the nanometric scale that present photothermal transductors
(PTs) with absorption in the biological window. Near infrared
irradiation (NIR) is known as a biological window since it is hardly
absorbed by water and blood cells and can penetrate deeply into
the body. PDT is based on PTs that can use NIR light to produce
reactive oxygen species which induce tissue destruction. On the
other hand, PTT makes use of specific PTs that can eﬀectively
transform NIR light into local heat, surpassing the traditional
hyperthermia methods such as hot-water bath or heated blood
perfusion.43 Nanogels composed of PTs and diﬀerent polymers are
ideal nanodevices for PTT because of their controlled size and
architecture, biocompatibility, degradation ability, physical proper-
ties, accumulation in tumors, loading capacity, and postsynthetic
modification.14 Moreover state-of-the-art drug delivery systems
have emerged that make use of thermoresponsive polymers
that can swell or shrink with the temperature in combination
with PTs.44 The local heat produced by PTs upon exposure to
specific radiation causes the transition of the thermoresponsive
polymer and expels the drug retained in it.
Gold nanoclusters have proven to be useful agents for PTT
after they were shown to have an absorption in the NIR region
four times higher than conventional photo-absorbing dyes.
More specifically, gold nanorods (AuNRs) have been extensively
explored due to their aspect ratio that enables eﬃcient NIR
light absorption. Photoexcitation of metal nanostructures
causes local heating which is useful for PTT. Magnetic nano-
particles (Section 2.2) can also generate local heating when they
are exposed to an alternating magnetic field (AMF) acting as
magnetic transductors.45,46 Some of the most employed PTs
like gold nanoparticles (AuNPs) as well as magnetic and silver
nanoparticles (AgNPs) also have the advantage of acting as a
contrast agent for bioimaging. All these properties favor the use
of plasmonic hybrid nanogels as theranostic agents in chemo-
and thermotherapy as well as in in vitro or in vivo imaging.47
Table 1 summarizes recent examples that are discussed in the
following sections and highlights the potential of the plasmonic
NPs@nanogels as theranostic agents.
2.1.1. Gold@nanogels. AuNPs of diﬀerent shapes internalized
in nanogels have been widely explored. The synthesis of these gold
nanocomposites can be mainly achieved by two approaches:
(a) pre-synthesis of plasmonic nanoparticles and posterior seed
polymerization of the nanogel or internalization into it,48–51 or
(b) in situ generation of nanoparticles inside the nanogel.52–54
Gold hybrid nanogels (Au@NGs) have been reported as rele-
vant bioimaging devices. Siegwart et al.55 described uniformly
Fig. 1 Hybrid nanogels and their application in nanomedicine.
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crosslinked poly(ethylene glycol) (PEG) based nanogels synthe-
sized by atom transfer radical polymerization (ATRP) in which
AuNPs were entrapped. Cell uptake and internalization of these
nanodevices have been studied in human umbilical vascular
endothelial cells (HUVECs) and human mesenchymal stem
cells (hMSCs) validating an endocytosis mechanism. A similar
approach by Oishi et al.56 made use of the fluorescence resonance
energy transfer (FRET) between AuNPs and fluorescein isothio-
cyanate (FITC) in a PEGylated Au@NG. A caspase-3-responsive
system was designed to monitor the cancer response to therapy.
A pronounced fluorescence was observed when the activated
caspase-3 in apoptotic cells cleaved the Asp–Glu–Val–Asp peptide
that resulted in the release of the FITC and dequenching of its
fluorescence. The biodistribution of poly(acrylic acid) (PAA)
nanogels with AuNPs formed in situ was recently studied in
H22 tumor-bearing mice.57 Gels mainly accumulated in the
liver and spleen because of their capture by phagocytic cells of
the reticuloendothelial system (RES) of these organs.
Au@NGs are interesting not only for bioimaging by employing
the optical properties of the gold, but also for other applications.
In the last decade, the use of nonspherical AuNPs as PTs in
Au@NGs enabled their advantageous application in PDT and PTT.
PEGylated poly-[2-(N,N-diethylamino)ethyl methacrylate] (PEAMA)
core nanogels with AuNPs post-synthesized by reduction of Au(III)
ions reported by Nakamura et al.58 showed high biocompatibility
and remarkable photothermal eﬃcacy. PTT in response to
514.4 nm light was achieved in HeLa cells, killing only the cells
in the laser area with low IC50 values depending on the gold
concentration of the nanogel. One of the most relevant examples
in this field is the PPT and PDT synergistic combination from
Kim et al.59 with Pluronic based nanogels loaded with AuNRs as
the PTT agent and chlorin e6 (Ce6) as the photosensitizer.
In vitro SCC7 cell line and in vivo SCC7 tumor bearing mice
remarkably enhanced the combination of PTT and PDT. But
even more interestingly, the tumor decreased in size when the
PDT was applied before PTT. When PTT was applied first the
combined therapy was not so eﬀective as with just PTT. This
comparative study therefore revealed a more convenient way
to the use of photo-therapies. The radiosensitizing potential
of gold containing nanogels enhancing the biological eﬀect of
X-irradiation was studied with PEGylated polyamine nanogels
containing AuNPs.60 This report proved that these devices
enhanced the cell radiosensitivity because of the induction of
apoptosis and the inhibition of DNA double-strand break repair
by Au@NG mediated endoplasmic reticulum stress. A combi-
nation of chitin nanogels with AuNPs and MnO2 rods was also
used for radiofrequency (RF) assisted hyperthermia.61 Au@NGs
showed better results in the ablation of T47D cancer cells than
the bare nanogels. Au@NGs formed by thermoresponsive polymers
controlled by PTs were used as smart drug delivery systems in
combination with hyperthermia. Thus, these nanogels are thera-
nostic systems with drug delivery, hyperthermia, and bioimaging
capabilities. Poly(N-isopropylacrylamide) (PNIPAm) is a thermo-
responsive polymer with a lower critical solution temperature
(LCST) of around 32 1C which is suitable for medical applications.
PNIPAm based nanogels were reported in combination with
AuNPs in a core–shell fashion.62 Au@PNIPAm nanogels were
employed in cell imaging trespassing cellular barriers to enter
the cytoplasm. 5-Fluorouracil (5-FU) served as a model anti-
cancer drug to test the viability of HeLa cells upon exposure to
515 nm laser. Cell death increased significantly in the drug
loaded systems in comparison to non-loaded ones, which
demonstrated the higher therapeutic efficacy of the combined
chemo-photothermal treatments. P(NIPAm-co-AA) nanogels with
incorporated gold nanoclusters were employed as a doxorubicin
(DOX) delivery system.63 In this case, the dual thermo- and
pH-responsive systems were decorated with tumor targeting
peptides like (CRGDRCPDC)-SH (iRGD) that showed good results
in HUVECs and extravascular tumor cells (B16). More convenient
PTs like gold nanorods (AuNRs) were studied as building blocks in
nanogel based drug delivery systems. Kawano et al.64 proved that
silica coated AuNR core–shell PNIPAm hybrid nanogels underwent
phase transition and accumulated in NIR irradiated target sites.
A similar system was used as a NIR guided DOX delivery system.65
After NIR irradiation the accumulation in the tumor following
systemic administration was enhanced with almost a total tumor
growth inhibition as well as lung metastasis (Fig. 2).
Gold–silver nanorods (Ag–AuNRs), which can absorb NIR
photons more efficiently than spherical gold and silver nano-
particles but combining their basic properties, were used as PTs
Table 1 Plasmonic hybrid nanogels as theranostic agents
Plasmonic NPs Polymer Stimuli Application Theranostic agent Ref.
AuNPs PEG NIR light Imaging (internalization) AuNPs 55
AuNPs PEAMA–PEG Caspase-3 Imaging (FRET, internalization) FITC 56
AuNPs PAA NIR light Imaging (biodistribution) Au Nanoclusters 57
AuNPs PEAMA-PEG NIR light Hyperthermia AuNPs 58
AuNRs Pluronic NIR light PTT and PDT Ce6 59
AuNPs Polyamine X-rays RF hyperthermia — 60
AuNPs-MnO2NRs Chitin Radiofrequency RF hyperthermia AuNPs–MnO2NRs 61
AuNPs PNIPAm-IPN Temperature Hyperthermia – drug delivery 5-FU 62
Au nanoclusters P(NIPAm-co-AA) Temperature Hyperthermia – drug delivery DOX 63
AuNRs PNIPAm NIR light-temperature Hyperthermia – drug delivery — 64
AuNRs PNIPAm NIR light-temperature Hyperthermia – drug delivery DOX 65
Au–AgNRs PAA-aptamers NIR light Hyperthermia – drug delivery DOX 66
Au–AgNPs PS-PEG NIR light Hyperthermia – drug delivery Curcumin 67
AgNPs P(NIPAm-co-AA) pH Imaging – drug delivery Dipyridamole 69
AgNPs P(NIPAm-co-DMAEA) pH Imaging – drug delivery Insulin 70
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in polyacrylamide based nanogels, crosslinked by complemen-
tary DNA strands. Nanogels were functionalized with DNA
aptamers for specific tumor cell targeting.66 DOX was loaded
into DNA aptamers that responded upon local heating by NIR
irradiation of the PT releasing the drug. Studies in CCRF-CEM
cells and in the Ramos cell line as the control demonstrated low
cytotoxicity of the nanogels as well as high specificity for tumor
cells after NIR irradiation. Bimetallic gold–silver nanoparticles
were also reported in core–shell polystyrene/PEG based nano-
gels.67 Au–Ag@NGs were able to encapsulate drugs like curcumin
that has pro-apoptotic effects. Upon NIR light exposure, the
release of drug could be triggered by thermoresponsivity of the
outer PEG shell to local temperature increase. In vitro compara-
tive study of these systems in B16F10 cells revealed an enhanced
effect of chemo- and thermotherapies.
2.1.2. Silver@nanogels. AgNPs present interesting properties
that encouraged various research groups to incorporate them into
nanogel architectures.68 AgNPs have well-known antimicrobial prop-
erties as well as optical properties for potential biodiagnostic
imaging. In the core–shell Ag@NGs of P(NIPAm-co-AA) reported by
Wu and Zhou69 the AgNP core acted as an optical identification code
for tumor cell imaging, while the P(NIPAm-co-AA) gel shell served as
the drug carrier with a high loading capacity of dipyridamole as a
model drug. Because of the pH response of the P(NIPAm-co-AA)
shell, the physicochemical environment of the AgNPs changed.
This alteration affected the optical properties of the core and also
modified the mesh size of the gel. This phenomenon was used to
regulate the drug release behavior in the B16F10 cell line. A similar
approach was applied to deliver insulin by employing a AgNP core
and a pH-responsive nanogel shell of poly(4-vinylphenylboronic
acid-co-2-(dimethylamino)ethyl acrylate) [p(VPBA-co-DMAEA)].70
2.2. Magnetic@nanogels
Within nanomaterial–nanogel composites, magnetic nano-
particles have attracted interest because of their application
as PTs and in imaging. In the past, the most common metho-
dology for preparing superparamagnetic iron nanoparticles
(SPION)71 consisted of reduction and coprecipitation of ferrous
and ferric salts in aqueous media in the presence of stabilizers.
This procedure has led to several commercial products like
Feridexs (Ferumoxides),72,73 Resovists (Ferucarbotran),73–75 and
Ferumoxtran-10s (Combidex).73,74,76 As their biodistribution
depended on their size and surface modification, much effort
has been made in developing magnetic nanomaterials with
increased colloidal stability under physiological conditions. More-
over, the research focus was on improving contrast properties
while lowering cytotoxicity, maintaining longer blood half-life,
improving biocompatibility, and enhancing tissue/organ targeting
ability as well as pharmaceutical efficacy due to surface function-
alization.77 Today, to accomplish the requirements for safer and
more efficient nanostructure-based contrast agents, the developed
materials have become more complex such as nanoclusters,78
polymersomes,79,80 nanocomposites,81–88 and nanogels.89–93
Considering the obtained impressive biodistributions and remark-
able magnetic resonance imaging (MRI) properties, the following
section presents recent developments of hybrid nanogels for
magneto-transducers (MTs) and MRI.
MTs like SPIONs were used as an alternative to PTs. As an
example, g-Fe2O3 magnetic NPs were internalized in poly(vinyl
alcohol-b-N-vinylcaprolactam) [P(VA-b-VCL)] based nanogels for
glucose-, pH-, and thermo-responsive release of DOX.94 AMF
induced heating could be generated because of the super-
paramagnetic properties of the SPIONs that accelerated the drug
release performance of the system. Chiang et al. also reported
the use of AMFs to enhance drug release95 from hybrid hollow
nanogels formed with PEG, AA, and PNIPAm, and crosslinked
by photo-initiated polymerization of 2-methacryloylethyl acrylate
(MEA). The DOX loaded nanogels exhibited accelerated drug
release in response to pH reduction and hyperthermia. Magnetic
properties of the nanogel were employed not only for AMF
Fig. 2 (A) Hybrid nanogel synthesis and (B) NIR laser induced targeted therapy using the hybrid nanogel. Reprinted with permission from ref. 65.
Copyright 2014 American Chemical Society.
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therapy but, moreover, for guided transport toward the target
and MIR. Enhanced in vitro cytotoxicity against HeLa cells in
comparison with free DOX demonstrated the great potential of
the multimodal theranostic system capable of combining
hyperthermia and chemotherapy (Fig. 3).
MRI is a widely known noninvasive imaging technique
that achieves notable high spatial and temporal resolution. It
displays contrast by tracking changes in water proton density
and longitudinal (T1) or transversal (T2/T2*) relaxation times of
protons in normal and diseased tissues.96 Since their first use
as MRI contrast agents 30 years ago,97 iron oxide nanoparticles
have gained much attention because of their ability to drama-
tically shorten T2/T2* relaxation times and therefore produce a
decreased signal intensity in T2/T2* weighted MR images. With
their specific accumulation in the liver, spleen, and bone marrow,
their high magnetization, high contrast visualization compared to
conventional paramagnetic T1 contrast agents, they have exerted a
large impact on the field of molecular and bio-imaging.98
In spite of a multi-modal approach for magnetic nanogels,
Kim et al.92 developed a self-fluorescent and, at the same time,
high-relaxivity T2-weighted MRI contrast agent for both MRI
and optical bio-imaging. The formulation was achieved by
electrostatic assembly and crosslinking of poly(g-glutamic acid)
(g-PGA) coated manganese iron oxide (MnFe2O4) nanoparticles
with the positively charged polyelectrolyte poly(L-lysine) (PLL).
During the ionic gelation process, glutaraldehyde was added to
the mixture which provided structural integrity to the nanogel
and involved the formation of a self-fluorescent chemical bond.
These fluorescent bonds were generated by the crosslinking of
PLL with the glutaraldehyde monomer. Finally, PEG was con-
jugated to the surfaces of the MnFe2O4@PGA–PLL(PEG) nano-
gels. The r2 value, which is known as relaxivity, is the reciprocal
of the T2 relaxation time per unit concentration of metal ions.
This value was 382.6 (Fe +Mn) mM1 s1 for the nanogel, two fold
higher as compared to the r2 of conventional SPION contrast
agents such as Feridexs and Resovists (Table 2). The remarkable
increase in r2 resulted from the synergistic magnetism of the
multicore MnFe2O4 nanoparticle satellites that were embedded in
the nanogels. Moreover, MnFe2O4@PGA–PLL(PEG) nanogels also
generated a strong fluorescence signal indicating that these
compounds can be used as an imaging technique in living tissues.
In vivo NIR fluorescence and MRI of the lymph node in a mouse
model highlighted the nanogel’s passive targeting ability to
successfully migrate from the injection site to the lymph node.
The results suggest that after the incorporation of therapeutic
moieties these systems could be a potent tool in theranostic
technology.
A similar approach in multi-modality was followed by Jiang
et al.90 when engineering pH and temperature sensitive mag-
netic nanogels conjugated with Cyanine 5.5-labeled lactoferrin
(Cy5.5-Lf) for MRI and fluorescence imaging of glioma in rats
(Fig. 4). In this study, citric acid coated SPIONs were incorpo-
rated in nanogels by free radical dispersion polymerization
with NIPAm and AA as environmental sensitive monomers,
Fig. 3 DOX-loaded hybrid nanogels as a multifunctional anticancer theranostic system. Reprinted with permission from ref. 95. Copyright 2013
American Chemical Society.
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and N,N0-methylenebisacrylamide (MBAAm) as the crosslinker.
After polymerization, the surface coating was achieved by
peptide coupling chemistry mediated conjugation of Cy5.5-Lf
providing both a dual imaging modality and a targeting ligand
for specific targeting of lipoprotein receptor-related protein
1 (LRP1) expressing cells. The obtained nanogels showed an
r2 value of 142.7 mM
1 s1, similar to that of Resovists, and
revealed pH and temperature sensitiveness for enhanced targeting
modalities. In fact, SPION@NIPAm-AA-Cy5.5-Lf nanogels were
hydrophilic and swollen under physiological conditions (pH 7.4,
37 1C), which could prolong the blood circulation time, but became
hydrophobic and shrunken in the acidic environment of tumor
tissues (pH 6.8, 37 1C). As a result, they could be more easily
accumulated in tumor tissue and internalized by tumor cells.
Cellular uptake studies on both rat C6 glioma cells (high LRP1
expression) and human umbilical vein endothelial (ECV 304) cells
(no LRP1 expression) interestingly revealed that the cellular uptake
of both SPION@NIPAm-AA-Cy5.5-Lf nanogels and NIPAm-AA nano-
gels at pH 6.8 was significantly higher than that at pH 7.4. These
results suggested that the nanogels’ hydrophilic/hydrophobic
transition and their change in size would increase their cellular
uptake, as well as improve their internalization in malignant
tissues. SPION@NIPAm-AA-Cy5.5-Lf nanogels were applied in vivo
and their imaging properties were evaluated in rats bearing
C6 glioma with both MRI and fluorescence imaging technique.
As a result, histopathological analyses obtained significant
targeting ability for SPION@NIPAm-AA-Cy5.5-Lf nanogels on
gliomas both in vitro and in vivo.
Even though such impressive investigations have been per-
formed as mentioned above, SPIONs generally provide some
conceptual disadvantages that may limit their advanced clinical
use. On the one hand, T2 contrast agents are negative contrast
agents that can lead to signal-decreasing eﬀects. As a result, the
obtained dark signals could be mistaken for other pathogenic
conditions leading to images of lower contrast than T1 con-
trasted images. On the other hand, the high susceptibility of T2
contrast agents might induce distortion of the magnetic field
in the neighboring tissues. This background distortion is the
so-called susceptibility artifact, which can yield obscure images
and ruin the background around the malignant tissue.71,96 There-
fore, themost used clinical contrast agents are based on gadolinium
complex T1 agents such asMagnevist (Table 2). Since these commer-
cially available T1 agents provide a relatively short blood half-life and
low contrast eﬃciency due to low relaxivity values,99 the scientific
community aimed to improve their clinical impact through nano-
technology.77,96 As an example, Soleimani et al.91 recently developed
small nanogels (B10 nm diameter) based on poly(ethylene glycol)
methyl ether methacrylate (PEOMA) and N-(2 aminoethyl) metha-
crylamide hydrochloride (AEMA) as monomers, and ethylene glycol
dimethacrylate (EGDMA) as the crosslinker. The nanogel’s surface
was decorated with an iso-thiocyanate derivative of the clinically
used chelate diethylenetriaminepentaacetic acid (DTPA) which
was able to complex gadolinium (Gd(III)) ions out of an aqueous
GdCl3–nanogel solution mixture. Compared with the clinical agent
Magnevists (Gd(III)–DTPA),99 the Gd(III) coated nanogels provided
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at the same dose in T1 weighted MR images of C.B.-17 SCID
mice bearing MDA-MB-231 tumors achieved for nanogels indi-
cated an increased accumulation in the tumor due to enhanced
circulation in the vasculature.
A similar observation has been made in another approach
incorporating Gd(III) ions into a nanogel matrix by Lim et al.89
Here, GdCl3 was coordinated to branched polyethyleneimines
(bPEI) through an inverse miniemulsion technique of Tween
80 stabilized water droplets in cyclohexane. The obtained
physically crosslinked nanogels (160 nm in diameter) were
subsequently modified with a Cy5.5 dye to yield nanogels with
a dual-imaging modality. Moreover, the labeled nanogels were
coated with linear poly(ethylene glycol) N-hydroxy succinimide
(PEG-NHS) as a stealth agent in order to increase the blood
circulation time. As expected, low cytotoxicity and high deform-
ability in terms of Young’s modulus were obtained, which
subsequently led to minimal filtration by the RES and therefore
increased passive accumulation in the tumor of a SCC7 tumor
bearing mouse. Interestingly, no enhanced T1-weighted MRI
contrast was observed (r1 = 2.1 mM
1 s1), but the remarkable
r2 value was 82.6 mM
1 s1 for T2-weighted MRI. As T1 and T2 are
known to rely on the number of Gd(III) ions or the size,100 the
dense multi Gd(III) complex, represented as nanogel, resulted in
a transverse relaxivity that lied in the range of SPIONs. Finally,
these nanogels should be considered as potential candidates for
theranostic purposes since the bPEI core surface could be easily
modified with suitable drugs and bioactive molecules.
A study that tested diﬀerent chelators for eﬃcient Gd nanogel
formation was recently performed by Lux et al.101 They designed
polyacrylamide (PAAm) based nanogels with diﬀerent acrylic
DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)
and DTPA based Gd(III) chelate complexes as crosslinkers.
Similar to the work of Soleimani et al.,91 r1 relaxivities in the
range of 9.7–17.6 mM1 s1 were obtained which were 3–4 fold
higher than the values of commercially available agents such
as Magnevists (Table 2). Since Gd(III) ions were embedded
by crosslinking in the nanogel matrix, DTPA-based nanogels
were more inert against transmetallation than Magnevists,
suggesting that crosslinker chelates may represent an important
approach towards stable metal-chelating biomedical agents.
As this methodology appeared in two steps, namely, the acrylic
chelate Gd(III) complex formation followed by free radical
emulsion polymerization with PAAm, incorporation of the
crosslinkers into nanogels with a biocompatible and biodegrad-
able polymer backbone might be a promising perspective
towards clinical relevance.
Fig. 4 (A) Schematic representation of SPION@NIPAm-AA-Cy5.5-Lf. (B) In vivo studies: MRI, optical imaging, and histopathological analysis of rats
bearing gliomas treated with saline as a control (upper row), SPION@NIPAm-AA-Cy5.5-Lf nanogels (middle row), and NIPAm-AA nanogels (lower row),
respectively. Reprinted from ref. 90. Copyright (2013), with permission from Elsevier.
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As shown in this section, most of the presented nanogel
based MRI contrast agents are still in the preliminary stage
of in vitro and in vivo testing. Several key issues have to be
addressed to provide nanogel based MRI contrast agents with
clinical relevance. These issues mainly deal with pharmaco-
kinetics, long-term stability, and toxicological eﬀects. Therefore,
intensive research is necessary to accomplish the ultimate task
of using nanogel based MRI contrast agents for molecular and
bio-imaging and thus achieve the transition of these concepts
from bench to the bedside.
2.3. Other nanomaterials–nanogels: quantum dots, porous
silica nanoparticles, and nanostructured carbon materials
As shown in Sections 2.1 and 2.2, plasmonic and magnetic
nanoparticles have been playing a significant role in the develop-
ment of novel stimuli-responsive nanogel composites for potential
application in nanomedicine. In addition to these examples, a
great deal of eﬀort has been devoted to creating new types of
nanomaterial–nanogel composites with enhanced functions,
including the use of QDs, porous silica nanoparticles (PSNPs),
and nanostructured carbon materials (Table 3). This section
highlights the features of such nanomaterials as part of stimuli-
responsive hybrid nanogel systems and their applications for
delivery of therapeutic agents.
2.3.1. Quantum dots@nanogels. To fulfill the need for tracking
certain biomolecules or cells by in vitro/in vivo imaging, development
of specific biocompatible labels is an inevitable task for the study
and understanding of the role of novel drug delivery systems. In this
regard, QDs-containing nanogel composites have been reckoned as
desirable inorganic–organic hybridmaterials in optical sensing and
imaging due to their intriguing luminescence characteristics and
electronic properties of QDs such as bright fluorescence, broad
absorption with narrow symmetric emission spectra, remarkable
photostability, and biocompatibility.102–110 QDs are nanometer-
order semiconductor crystals that exhibit discrete energy levels
and their electronic and optical properties are determined only
by their size. Depending on their diameter, QDs therefore shine
in different colors when exposed to ultraviolet light (e.g., blue =
2 nm QDs; red = 6 nm QDs).111,112
In the last few years, diﬀerent strategies have been used to
obtain stimuli-sensitive QDs-based fluorescent probe nanogel
composites as drug delivery systems with simultaneous imaging
and biosensing. A simple approach is to incorporate surface-
modified QDs into the polymer network of the preformed
nanogels. For example, Hasegawa et al. prepared monodisperse
hybrid nanoparticles of 38 nm by mixing protein-coated QDs
with amino-modified cholesterol-bearing pullulan nanogels
(CHPNH2-QD) in phosphate buﬀered saline (PBS) solution for
30 min at room temperature.113 Although the incorporation
of QDs into unmodified, neutral cholesterol-bearing pullulan
(CHP) nanogels was suppressed, electrostatic interaction between
negatively charged QDs and positively charged amino-containing
nanogels induced the successful formation of the hybrid nanogel
complex. Furthermore, the QDs@CHPNH2 nanogel composite
did not form aggregation after its internalization into various
human cells. In a similar way, Rejinold et al. reported the
preparation of multifunctionalized biodegradable nanogels by
simply mixing mercaptopropionic acid-capped CdTe Ds and
chitin nanogels in an aqueous solution.114 The unreacted –OH
and –NH2 groups of the repeating N-acetylglucosamine units,
that compose the chitin chains, acted as anchor points to
sequester Cd2+ ions and further immobilize CdTe QDs in the
nanogel matrix. The obtained CdTe QDs–chitin nanogel com-
posite as a fluorescent probe and drug delivery system could be
easily loaded with bovine serum albumin (BSA) showing pro-
mising applications for simultaneous bioimaging during drug
release under local environmental conditions. Following the
same trend, different nanogel networks have been used to seize
QDs in nanomedicine as sensing and imaging materials.115–117
Nevertheless, the design of multitasking hybrid drug carriers
capable of integrating various functionalities in one single
nano-object is highly desirable.118–120 Recently, Yang et al.
developed an interesting QDs@polypeptide nanogel composite
with a dual hydrophilic/hydrophobic character (Fig. 5).41 The main
formation of the novel hybrid nanogels can be summarized in two
steps: (a) specific metal–affinity interaction between hydrophilic
glutathione-coated CdSe–ZnS QDs and N-terminal polyhistidine
sequences of PC10A or PC10ARGD coiled-coil polypeptides and
(b) nanogel formation and final encapsulation of QDs via self-
assembly. The thus obtained pH and temperature dual responsive
QDs-polypeptide nanogels of 23 nm in diameter were further
loaded simultaneously with hydrophobic and hydrophilic dyes
(2-amino-4,6-bis-[(4-N,N0-diphenylamino)styryl]pyrimidine and
fluorescein sodium, respectively) as model drugs. Their evalua-
tion in HeLa cancer cells revealed remarkable overexpressed
avb3-integrin receptors for simultaneous optical pH-sensing
and targeted delivery of drugs.
Other strategy for the preparation of QDs@nanogel compo-
sites can be the in situ synthesis of QDs in the interior of the
nanogel. This approach has been illustrated by Wu et al.121 by
conducting a successful in situ synthesis of CdSe QDs inside of
a temperature- and pH-sensitive polysaccharide-based nanogel
network. In the construction of a hybrid QDs-nanogel complex,
the synthesis of QDs within the gel matrix oﬀered a confined
growth process that could improve the chemical interaction of
quantum nanocrystals with the polymeric gel to confer them
optimal dimensions and stable optical signals. Following a
similar strategy, Zhou’s group moved forward in their research
and developed pH sensitive CdSe@CHI–poly(methacrylic acid)
and temperature responsive Bi2O3@PVA nanogels by in situ
formation and immobilization of QDs.122,123 The main goal of
such custom-designed engineering nanohybrid systems was to
integrate multifunctionalities for simultaneous biosensing,
bioimaging, and effective therapy.
2.3.2. Porous silica nanoparticles@nanogels. PSNPs have
received significant attention in the last decade because of their
superior and tunable physicochemical properties making them
ideal in many fields of application such as catalysis, adsorption,
sensors, and biomedical technology.124,125 PSNPs are particu-
larly attractive as drug delivery systems owing to their large
surface area, tunable pore size, non-toxic nature, facile surface
functionalization, high loading and controlled drug release,
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and excellent biocompatibility.126–132 Although the stimuli-
responsive silica-based nanogels can be a fascinating subject
of study, a few studies in this topic have become known in the
recent years. Chai et al. reported a surfactant-free emulsion
polymerization and biomimetic template approach for the
synthesis of thermoresponsive hybrid nanogel-silica core–shell
particles.133 Poly(N-isopropylacrylamide-co-2-(dimethylamino)-
ethyl methacrylate, methyl-chloride) quaternized nanogel particles
were in situ covered with silica and the obtained nanogel–silica
particles were further loaded with aspirin. The drug delivery
nanogel–silica system showed a controlled slow drug release of
more than 24 h, while the non-templated silica nanogel practi-
cally released its cargo within 5 h. This work demonstrated that
nanogel particles covered with a silica shell can effectively
retard or control the drug release.
Motivated by the potential application of spherical hollow
silica matrices, Liu et al. constructed a thermoresponsive drug
release system based on hollow silica nanospheres coated with
a PNIPAm nanogel shell.134 The prepared hollow silica nano-
gels showed good biocompatibility under in vitro cytotoxicity
evaluation as well as excellent thermoresponsive controlled-
release behavior of rhodamine B (RHB) during release studies.
This hollow silica PNIPAm-nanogels appear to be highly suitable
for stimuli-responsive controlled-release drug delivery applications.
Similar systems have been developed using nanostructured meso-
porous silica covered with stimuli-responsive polymer shells in
order to retard and control the release rate of the cargo under
environmental stimulus control.135–137 The development of
hollow or mesoporous silica materials offers new possibilities
for incorporating specific drugs within silica cavities followed
by controlled release of its cargo from the matrix due to its well-
defined structure.
2.3.3. Nanostructured carbon materials@nanogels. Over
the past several decades, nanostructured carbon materials in
various allotropic forms (e.g., fullerenes, nanotubes, graphene,
and diamonds) have received overwhelming attention because
of their unique physical and chemical properties tunable in a wide
range, such as high specific surface area, narrow pore width, large
pore volume, low density, excellent electronic conductivity,
and high thermal and mechanical stability.138–140 Considering
such features, carbon-based nanostructured materials have been
extensively studied in many different fields, including energy
conversion and storage, catalysis support, adsorption, gas
storage, water treatment, and more recently biomedicine.141–143
The use of nanostructured carbon materials with tunable func-
tionalities promises great advances in drug delivery and thera-
peutic treatment.22,144–146 For example, the spherical fullerene
C60, also known as buckminsterfullerene,
147 has been considered
as a photosensitizing agent for non-invasive photodynamic therapy
treatments owing to its photo-physical abilities to absorb energy at
a specific wavelength in the UV range and to further transfer the
excited energy to oxygen molecules, resulting in the generation
of cytotoxic agents (singlet oxygen).148–150 Recently, Kim et al.
synthesized a photo-responsive C60@glycolchitosan-based nano-
gel composite via self-assembly of 2,3-dimethylmaleic acid-grafted
glycol chitosan chains and C60 nanoparticles.
26 This hybrid
nanogel showed an innovative ability for endosomal pH targeting,
through an enhanced singlet oxygen generation and high photo-
dynamic tumor cell ablation at pH 5.0. This system displayed
great capability for its use in selective endosomal delivery of
photosensitizer drugs to tumor cells.
Despite the interesting properties of the fullerenes, the
spotlight of scientific research has been cast on the utilization
of other nanostructured carbon materials in recent years. In terms
of mechanical, optical, conductive, and thermal properties, carbon
nanotubes (CNTs) have received enormous attention in the field of
bioapplications.151–153 Although many research groups have incor-
porated CNTs into hydrogel polymers154 in order to reinforce gel
structure, increase electrical conductivity, and enhance NIR sensi-
tivity properties, only a few studies have reported the preparation of
the CNT–nanogel composite for drug delivery purposes.23,24,155
Nevertheless, this is a topic that will be much studied in the
forthcoming years. Very recently, Qin et al.155 published the
development of a NIR triggered DOX delivery system based on
CHI-coated CNT encapsulated in a PNIPAm nanogel (PNIPAm@
CHI–CNT, Fig. 6). In this work, they reported a high DOX loading
capacity of B43% and a faster drug release at 40 1C and pH 5.
Moreover, due to the CNT these nanogels showed a triggered
DOX release upon NIR irradiation.
Although CNTs have been actively researched for their
possible application in nanomedicine since the late 90s, graphene
has garnered tremendous attention in biomedicine in the past
Fig. 5 (a) Schematic representation of the QDs@polypeptide nanogel.
(b) Confocal fluorescence images of HeLa cells incubated with the QDs@
polypeptide nanogel; green and red channels show the green dye (fluorescein
sodium) signal and red QDs signal. Reproduced from ref. 41 with permission
from The Royal Society of Chemistry.
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few years because of its high mechanical strength, great optical
absorbance, excellent thermal conductivity, and low toxicity.156–159
Graphene is a sheet-like two-dimensional sp2-bonded carbon
structure and a single layer of graphene sheet has a thickness
of 0.34 nm (one-atom thick). Particularly, reduced graphene
oxide (rGO) is capable of adsorbing NIR light and converting
such optical energy into thermal energy.160–162 Under this
consideration, Wang et al. constructed a photothermal NIR
light-responsive drug delivery platform based on CHI-modified
rGO crosslinked with NIPAm and polyethylene glycol-diacrylate
(PEG-d).163 The rGO hybrid nanogel was further loaded with
DOX as an anticancer drug showing high loading capacity up to
48 wt%. In vivo studies showed that the photothermal response
of the rGO to NIR irradiation led to a rapid rise in the temperature
of the surrounding gel and resulted in a fast release of the loaded
DOX with high local controllability. The weight composition of
rGO/nanogel not only had a dramatic effect on the thermo- and
photo-responsive properties of the hybrid nanogel composite,
but also a defect or excess in rGO could switch-off or switch-on a
specific skill of the rGO–nanogel complex.161 For example, at a
rGO composition ofB47.5 wt%, the nanogel composite showed
both thermo- and photo-sensitivities, while at lower (r32 wt%)
or higher (Z64.5 wt%) rGO composition the hybrid nanogel only
presented thermo- or photo-sensitive properties, respectively.
Furthermore, an excess of rGO (Z78.5 wt%) caused the nanogel
composite to lose its responsive properties.
Lately, a particular allotropic form of carbon has been
considered for its use in bioimaging, biosensing, and therapeutic
applications: diamond. Particularly, nanodiamonds (NDs) are
three-dimensional sp3-bonded carbons with a distinctive faceted
surface architecture where, depending on the size and morphol-
ogy, the sp3-surface of the NDs is stabilized through either
termination with functional groups or reconstruction of sp3
carbon into sp2 carbon. The presence of such surface functional
groups on the NDs allows them (i) to coordinate water mole-
cules around the surface and ensure well-dispersion in an
aqueous medium/matrix and (ii) to interact chemically with
specific molecules or drugs in a biocompatible environment.164,165
Furthermore, NDs have demonstrated excellent biocompatibility in
many in vitro and in vivo studies.166,167 Very recently, the rational
design of therapeutic contact lenses through the incorporation
of NDs into nanogel matrices as eﬀective ocular drug delivery
platforms has been demonstrated by Kim et al.168 They have
synthesized a drug-loaded ND@nanogel composite via cross-
linking polyethyleneimine-coated NDs and partially N-acetylated
CHI in the presence of timolol maleate. The timolol-containing
NDs@nanogels were then embedded within a hydrogel matrix
Fig. 6 Schematic representation of DOX loaded PNIPAm@CHI-CNT and
the triggered drug release by NIR irradiation. Reprinted from ref. 155,
Copyright (2015), with permission from Elsevier.
Fig. 7 Schematic representation of (a) timolol-loaded ND@nanogel and (b) ND@nanogel embedded contact lenses. Reprinted with permission
from ref. 168.
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and cast into enzyme-responsive contact lenses (Fig. 7). The
main role of the coated NDs is to retain the timolol by short
distance chemical interactions and to avoid the premature
elution of the drug, but keeping it physically active for its further
release under degradation of the nanogel via lysozyme cleavage.
In addition to the improved timolol-controlled release, the
incorporation of a small amount of NDs into the lens matrix
enhances tensile strength and boosts elastic modulus by the
reinforcement of the polymer matrix. Overall, the obtained
lysozyme degradable, timolol-loaded ND@nanogel embedded
contact lenses not only had excellent water and oxygen perme-
ability, optical clarity, and improved mechanical properties, but
most importantly also displayed sustainable drug release under
lysozyme activation. This novel ND-based system provided an
interesting platform for the development of advanced enzyme-
triggered drug release devices for sustained therapy applications.
Undoubtedly, the use of QDs, PSNPs, and nanostructured
carbon materials to control the mechanical, optical, electrical,
and thermal properties of smart nanogel composites for
potential on-demand high-controlled drug delivery nanovehicles
has made tremendous advances in nanomedicine. However, the
capability of the nanomaterials, mentioned in this section, to
enhance hybrid nanogel composite abilities is still not fully
explored. We believe that forthcoming research on the topic
and further full-understanding of biological systems will change
dramatically today’s concepts and a huge progress in biomedical
technology will take place in a near future.
3. Polymer–nanogel composites
Composites of nanogels with other polymers not only extend the
applicability of these systems due to the multisensitiveness,169 but
moreover overcome some disadvantages of single networks as,
for example, slow-rate response,170 the hysteresis during repeated
swelling–shrinking cycles,171 etc. Based on the nature of the compo-
site polymer–nanogels can be classified into two categories: (a) IPNs
and (b) core–shell particles. The utilization of these strategies for
obtaining multiresponsive hybrid nanogels and their further appli-
cation in nanomedicine will be described in Sections 3.1 and 3.2.
3.1 Interpenetrated and semi-interpenetrated polymer
networks
To enhance the mechanical strength, the swelling/deswelling
response, and to add new sensitivities to a nanogel,
multicomponent networks as IPNs have been designed (Table 4).
IPNs are defined by IUPAC as ‘‘two or more networks that are at
least partially interlaced on a molecular scale but not covalently
bonded to each other and cannot be separated unless chemical
bonds are broken’’.172 The combination of the polymers results in
a polymeric system with a new profile. IPNs can be classified into
full IPNs (IPN)173 when the interpenetrated polymer is crosslinked
inside the first network, or semi-IPNs (sIPNs)27 when a linear
polymer is embedded within the first network.
There are two synthetic pathways for obtaining IPNs:174 (1)
simultaneous synthesis, where both monomers are mixed and
the polymers synthesized at the same time by noninterfering
routes175 and (2) sequential synthesis, where the second monomer
is polymerized in situ, inside the first single network.176
One of the major uses of IPNs is obtaining biomedically
relevant dual responsive hybrid nanogels with little interference
between stimuli.31 Several examples of IPNs for synthesizing
dual pH/temperature responsive networks as drug delivery
systems were published in the last decade.27,173,177–180 do
Nascimento Marques et al.181 found that the introduction of
pH-sensitive polymers to crosslinked PNIPAm particles not only
produced dual-sensitive materials but also allowed particle
stability to be adjusted depending on the desired application.
In this context, Xing et al.173 reported temperature/pH dual
stimuli responsive hollow nanogels with an IPN structure based
on a PAA and PNIPAm (PNIPAm/PAA IPN hollow nanogels).
These nanogels showed a high drug loading capacity of iso-
niazid (INH), an antitubercular drug, up to 668 mg INH per
gram of the nanogel. In vitro drug release studies showed an
acid triggered drug release behavior, thus making them a
potential stomach-specific drug delivery system.
Besides PNIPAm, other thermoresponsive polymers were
used in IPNs. Chen et al.180 reported the synthesis of a thermo
and pH dual-responsive nanogel of hydroxypropylcellulose–
poly(acrylic acid) (HPC–PAA) particles with sIPN polymer net-
work structure. The novelty of this system was that depending
on the chemical composition and the degree of crosslinking,
the thermoresponsive behavior could be shifted from the upper
critical solution temperature (UCST) to the LCST. Additionally,
oxaliplatin was successfully loaded in the nanogel showing a
high in vitro anticancer activity.
Another thermoresponsive system, based on poly(oligo
ethylene glycol) (POEG), was used by Zhou et al.,182 who com-
bined the advantages of linear PEG and temperature-responsive
polymers in a single macromolecular structure. They have
Table 4 Interpenetrating polymer networks in nanomedicine
Network Polymers Stimuli Application Ref.
IPN PNIPAm/PAA Temperature and pH Stomach-specific drug delivery system 31, 173 and 178
sIPN HPC/PAA Temperature and pH Oxaliplatin delivery 180
IPN CHI/POEG Temperature and pH Chemo-cryo cancer therapy 182
IPN P(NIPAm–Dex–PBA) Temperature and [glucose] Insulin delivery 170 and 220
IPN [P(NIPAm-co-FPBA)]/PAAm Temperature and [glucose] Nanoglucometer 171
IPN NaAlg/PAA pH Ib controlled release 184
sIPN CHI/PMAA pH TMZ release 123
IPN PNIPAM/PAA Temperature and pH Imaging by SERS 185
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designed a new class of pH-responsive CHI-based nanogels by
IPN of CHI chains into a POEG chain network (Fig. 8). The
POEG–CHI nanogels responded to the changes in environmental
pH and the cell internalization is facilitated by the positive
surface charge of the nanogels in the extracellular pH conditions
of the tumor (B6.0–6.2). More interestingly, the IPN enabled a
remote modulation of the pH response by external cooling/
heating (cryo/thermo treatment). The nanogel was loaded with
5-FU, a model anticancer drug, which could be released from the
drug carriers upon increased acidity in subcellular compart-
ments (B5.0). The in vitro studies in B16F10 melanoma cells
showed reduced toxicity in combined chemo-thermo treatments
but significantly enhanced therapeutic efficacy in combined
chemo-cryo treatments.
Additionally, the IPN strategy was extensively studied for the
production of glucose sensitive nanogels in order to address
the slow-time-response issue of the other insulin delivery
systems reported previously.183 Wu et al.170 reported the synthesis
of a nanogel dispersion with three interpenetrating polymer
networks consisting of PNIPAm, Dex, and poly(3-acrylamido-
phenylboronic acid) (P(NIPAm–Dex–APBA)). The particle size
could be tuned with the Dex content. The swelling behavior of
the nanogels at different glucose concentrations revealed their
sensitivity to glucose. Furthermore, the nanogels had good
biocompatibility with L-929 mouse fibroblast cells. The loading
amount of insulin was 16.2%, whereas drug release was
dependent on the composition of Dex and the glucose concen-
tration in the release medium. In vivo experiments have shown
the efficacy of the insulin-nanogels to decrease the glucose
levels in the blood of diabetic rats and the hypoglycemic effect
of the insulin-nanogels was similar to that of the free insulin.
They have further studied diabetes and developed a nanogluco-
meter based on a fluorescent hybrid nanogel glucometer (FNG)
for intracellular glucometry.171 This nanogel contained ZnO
QDs covalently bonded onto a crosslinked network of PAAm,
which was interpenetrated in a network of poly(N-isopropyl-
acrylamide-co-2-acrylamidomethyl-5-fluorophenylboronic acid)
[poly(NIPAm-co-FPBA)]. This double-network-structured FNG
responded to the glucose levels of the surrounding media and
converted the disruptions in the homeostasis of glucose level into
fluorescence signals at a fast time response. The high sensitivity
and selectivity together with the good penetration in model B16F10
cells showed the promise of the FNG for application as a nano-
glucometer. In this example, the IPN strategy was used in order to
overcome the problems during repeated swelling–shrinking cycles
that are inherent to the simple network systems.
Another application of the IPN strategy was the modification
of the release profile of diﬀerent drugs.123,184 In this context,
Babu et al.184 developed a pH-sensitive IPN of sodium alginate
(NaAlg) and AA for controlled release of ibuprofen (IB). While
NaAlg disintegrated in the intestinal fluid, PAA provided
pH-sensitivity to the nanogel.
Fig. 8 (A) Schematic illustration of POEG–chitosan nanogels with a semi-IPN structure. (B) TEM images of POEG–chitosan nanogels. (C) Effect of
molar ratio of fPOEG/CHI on the average hydrodynamic radius (Rh) of POEG-CHI nanogel particles. Reprinted from ref. 182 with permission from John
Wiley & Sons, Inc.
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Wu et al.123 reported the synthesis of hybrid nanogels based
on the immobilization of CdSe QDs in poly(methacrylic acid)
(PMAA) networks sIPN with CHI. They have shown that the
crosslinked structure conferred colloidal and structural stability
compared with the non-crosslinked hybrid nanogels. The
covalently crosslinked hybrid nanogels proved to have negligible
cytotoxicity, could sense the environmental pH change, and
regulated the release of anticancer drug, temozolomide (TMZ),
in the typical abnormal pH range of 5–7.4.
Very recently, a new application of the IPN strategy was
developed by Liu et al.185 They have synthesized an AgNP-loaded
PNIPAM–PAA interpenetrated microgel for its use in surface-
enhanced Raman scattering (SERS). SERS is an optical detection
technique with higher sensitivity than traditional techniques
and, more importantly, it can be used for detection in blood
and other biological environments.186 In this work, they have
proved that the SERS intensity can be reversibly tuned with
temperature or pH, showing an increase when lowering the pH
from 7 to 3 or rising the temperature from 20 to 45 1C. With this
study, new opportunities in the field of theranostics are open.
3.2. Core–shell polymer networks
Nanogels with core–shell architectures were designed to yield
separate but covalently bound compartments, which result in
inhomogeneous but chemically stable single particles. This
inhomogeneity can be exploited for the design of nanogels that
respond to multiple signals. Typical examples describe thermo-
responsive nanogels exhibiting more than one phase transition
temperature,169,187 amphoteric nanogels that swell in both
basic and acidic media but shrink near the isoelectric point,188
nanogels that are both thermo- and pH-responsive,133,169,188–192
core–shell nanogels with controlled drug delivery,193,194 etc.
The grafting of specific (macro-)molecules to the core of
nanogels was used to yield star-like core–shell nanogels, which
are active towards enhanced cell epitope recognition30,195,196 or
increased protein resistance of the nanogels.197–201 PEGylated
nanogels are the most common example of core–shell nanogels
in which PEG acts as the shell. The grafting of linear PEG
chains on the surface of the nanogels contributes to a drastic
increase in the bioavailability of the particle due to the protein-
resistant properties of PEG.202 Its use is widespread due to its
approval by the Food and Drug Administration (FDA) for pharma-
cological use. The readers are referred to the review by Knop et al.
for a more comprehensive discussion of PEG as the shell for
drug delivery applications.202
A review by Richtering and Pich extensively discussed the
peculiar swelling properties of stimuli-responsive core–shell
nanogels.203 It was observed that the mechanical properties
of such particles are determined by both core and shell, which
dynamically influence each other. The architecture of core–
shell particles confers physical constrictions to the swelling of
the two single compartments. This leads to varied LCSTs as well
as swelling degrees.
In the pioneering work of Jones and Lyon,189 which reported
in 2000 the first example of a core–shell nanogel, it is observed
that the shell swelling behavior plays a major role in the
swelling of the whole particle. This effect is especially observed
when a charged PNIPAm-co-AA polymer is in the shell rather
than its uncharged PNIPAM counterpart. When added to the
shell, the decreased interchain distance in the core polymer
leads to decreased LCST as well as lower swelling degree.
Since then, a large number of studies have been published
in this field describing the synthesis and characterization of
core–shell nanogels. A review by Hendrickson et al.204 in 2010
already described multifunctional core–shell nanoparticles. We
will therefore preferentially focus our attention on more recent
papers regarding core–shell nanogels applied in nanomedicine.
A number of studies reported the synthesis and characteriza-
tion of novel core–shell nanogels, as listed in Table 5.
The synthesis of core–shell nanogels was reported following
different procedures. The most common technique is the seed
precipitation polymerization, in which the already prepared
thermoresponsive core is used in its collapsed state for the
growth of the shell on its surface via a second step of radical
polymerization.30,188,189,191,195,196,205 Another widespread syn-
thetic technique is the crosslinking of amphiphilic micelles
preformed by self-assembly133,187,192,197,206 or the reversible
addition–fragmentation chain-transfer polymerization
(RAFT).169,187,190,200,206–208 All these synthetic methodologies
can give core–shell nanogels with facile scalability and low
polydispersity.
The imaging of core–shell nanogels was typically performed
via transmission and scanning electron microscopy (TEM,
SEM)133,169,187–189,191,198,199,206,209,210 or atomic force microscopy
(AFM).192,200,208,209 The visualization of the two distinct compart-
ments in polymer-only core–shell nanoparticles is usually
problematic due to the soft properties of these materials.
Table 5 Summary of the most recent and significant studies on core–shell nanogels
Core Shell Responsiveness Ref.
P(NIPAm-co-CMA) P(DMA-co-CMA) Temperature (LCST NIPAm + UCST nanogel) 187
P(MeO2MA) P(MeO2MA-co-OEGMA) Temperature (2 LCST) and pH 169
P(IADME-co-VIm) P(VCL) Temperature, pH (amphoteric) 188
OEG OEG or PEG Temperature 200
PEAMA PEG pH 201
Poly(DVB)-co-(PEG, NIPAm, MBA, MPA) PNIPAm-co-(MBA, MPA) Temperature 207
OEG PEG Temperature 208
BAP PEG Reducing conditions 210
PEAMA PEG pH 211




























































































6176 | Chem. Soc. Rev., 2015, 44, 6161--6186 This journal is©The Royal Society of Chemistry 2015
Nevertheless, TEM and AFM microscopy provided some nice
micrographs of core–shell nanogels displaying the distinct
environments, as shown in Fig. 9.189,191,192 The data obtained
by characterization via small-angle X-Ray scattering (SAXS) and
small-angle neutron scattering (SANS) were used to retrieve radial
structural information for the nanogels. The data were fitted to a
concentric core–shell model function to give a more accurate
description of the size of core and shell compartments.197,201,211
Among other biomedical applications, several studies were
conducted for the synthesis of core–shell nanogels as effective
carriers for short interfering ribonucleic acid (siRNA) delivery.
An interesting review about this subject was published in 2012
by Smith and Lyon.212
Glucose-responsive core–shell nanogels were developed
for the treatment of diabetes mellitus. Lapeyre et al.205 and
Zhao et al.198 developed systems that efficiently prolonged the
release of insulin in the presence of elevated blood glucose
levels. PNIPAm-based core–shell nanogels including a comonomer-
ized glucose-responsive phenylboronic acid (PBA) derivative in the
shell were synthesized.205 It was found that PBA forms stable
complexes with glucose, and as a result the increased hydrophilicity
of the complex leads ultimately to the swelling of the nanogels.
The synthesis of the thermoresponsive PNIPAm core occurred
via precipitation polymerization, and the collapsed cores were
subsequently used as seeds for the second analogous polymer-
ization step, which was performed to include the PBA deriva-
tives APBA or 4-(1,6-dioxo)-2,5-diaza-7-oxamyl phenylboronic
acid (DDOPBA) as the glucose-responsive comonomer together
with NIPAm. Core–shell nanogels obtained with DDOPBA were
used for biological studies because of their higher biocompat-
ibility at physiological pH, the pKa of DDOPBA being 7.8. The
swelling behavior of the PNIPAm–APBA core–shell nanogels
was extensively investigated in relation with glucose binding,
and a complex behavior was observed. At temperatures below the
LCST of PNIPAm (T = 32 1C), binding of glucose to the nanogels
led to swelling of the shell, which then allowed the relaxation of
the otherwise constrained core. Moreover, the swelling degree of
the shell was found to be a tuned response, directly proportional
to the glucose concentration. The results for PNIPAm–DDOPBA
nanogels were found to be very similar to those of PNIPAm–
APBA nanogels, although a higher transition temperature was
observed in this case. The breathing-in technique was used to
encapsulate FITC-insulin in the nanogels, and a prolonged
retention of the drug was observed for the loaded nanogels.
The release of insulin from PNIPAm–DDOPBA nanogels proved
to be dependent on the presence of glucose over a 9 h time
span, as shown from fluorescence spectroscopy.
Park et al.197 reported the synthesis of pH-responsive, core–
shell poly(aspartic acid)–PEG nanogels, which were also able
to prolong the release of insulin. A linear block copolymer of
PEG-co-poly(succinimide) (PEG-co-PSI) was synthesized, which
formed micelles via self-assembly. After micellation the PSI
residues were crosslinked with hexamethylenediamine to form
the precursor nanogel. Subsequently, an alkaline hydrolysis of
the PSI core led to the formation of the poly(aspartic acid)–PEG
nanogel (PAsp–PEG). Thus, the nanogel core turned hydrophilic
and pH-responsive. The PAsp–PEG nanogels were incubated in
a solution of recombinant human insulin, and its release from
the nanogels was investigated. The release curve was found to be
dependent on the pH: the release was completed within 48 h at
pH 7.4, while at pH 2 only 50% of the model drug was released in
the same time span.
Analogous protein carriers were developed as core–shell
nanogels. Chen et al. reported the synthesis of pH-responsive
hollow core–porous shell PAA nanogels that exhibited surpris-
ingly high loading capacities (800 wt% for BSA and 200 wt% for
DOX).209 The synthesis proceeded via the semi-interpenetration
of PAA with HPC, the latter being removed in a subsequent
step by alkaline hydrolysis, to give a core–shell nanogel of PAA
alone. The removal of HPC left a void in the nanogel core. It was
assumed that this structural organization was responsible for
the very high loading capacities obtained after incubation of
BSA and DOX. For BSA, the loading capacity was 8.0 mg per mg
nanogel. Interestingly, TEM images showed that the BSA loaded
nanogels became solid nanoparticles, while before encapsula-
tion the nanogels had been soft materials. For DOX, the loading
Fig. 9 TEM image of the controlled formation of microgels/nanogels. Adapted with permission from ref. 210. Copyright (2012) American
Chemical Society.
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capacity (2 mg per mg nanogel) was lower than that of BSA, but
nevertheless very high if compared with the values obtained by
other nanocarriers.213 The release behavior for BSA was shown
to be almost independent of the pH, indicating that the driving
force of encapsulation and release was not of electrostatic
nature, but dependant on hydrophobic interactions. Circular
dichroism spectra proved that the native structure of BSA was
retained after encapsulation and release. On the other hand,
the release profile of DOX was shown to be strongly dependent
on the pH. In more acidic conditions (pH 4.0), the release
of DOX was shown to be much faster than at a physiological
pH of 7.4.
Another example of a protein carrier was developed by
Bhuchar et al.206 Core–shell nanogels exhibiting a thermorespon-
sive poly(methoxydiethylene glycol methacrylate)-co-poly(2-amino-
ethyl methacrylamide hydrochloride) (MeODEGM-co-AEMA) core
and a shell of poly(2-methacryloyloxyethyl phosphorylcholine)
were synthesized via a one-step RAFT. The resulting nanogels
exhibited a thermoresponsive core with 2,2-dimethacroyloxy-1-
ethoxypropane as the crosslinker, which degrades in acidic con-
ditions. The nanogel loading occurred via incubation in a protein
solution (BSA, insulin, or b-galactosidase). The cationic AEMA
residues present in the core of the nanogels increased the binding
affinity of the oppositely charged proteins. The release of proteins
was investigated via BCA assay, and the observed rate increased
with decreasing pH, as expected from pH-degradable nanogels.
Moreover, the release rates were found to be dependent on the
size of the proteins: the smaller the protein, the faster its release
out of the nanogels. Table 6 recapitulates the most recent studies
on core–shell nanogels with controlled drug release.
Wu et al. reported the synthesis of an enzyme-degradable
polyphosphoester (PPE) core–galactosylated (Gal) PEG shell
nanogel for the treatment of hepatic carcinoma (Fig. 10).214
The synthesis of the nanogels proceeded via ring-opening
polymerization of 3,6-dioxaoctan-1,8-diyl bis(ethylene phos-
phate) (TEGDP) together with monomethoxy-PEG (mMePEG)
chains, initiated by stannous octoate in dimethylsulfoxide
(DMSO) at 60 1C. The resulting nanogels were coupled with
lactobionic acid in the presence of PEG–NH2 residues, assisted
by sulfo-NHS and 1-ethyl-3-(3-dimethylaminopropyl)carbodi-
imide (EDC) coupling agents, to give Gal-PEG chains. The galactosyl
ligand on PEG was used to target the asialoglycoprotein receptor
(ASGP-R), which is overexpressed in mammalian hepatocytes.215
The nanogels were loaded with DOX and incubated with HepG2
cells at 4 1C to investigate the receptor binding of Gal-nanogels,
and the flow cytometry data showed a remarkable increase of
fluorescence for Gal-nanogels compared to the non-galactosylated
ones. Addition of lactobionic acid to the cell environment showed
a competitive inhibition of the binding of Gal-nanogels on the
cell receptors. Induced hepatocarcinoma in rats was treated
with DOX-loaded Gal-nanogels, and a decrease in tumor mass
was observed for DOX-loaded Gal-nanogels compared to all
other samples and controls.
Moreover, biodegradable core–shell nanogels were reported
by Xing et al. with the synthesis of a PEGylated poly(L-cystine-co-
g-benzyl-glutamate) nanogel via ring-opening polymerization.199
The core was degradable under reducing conditions due to the
presence of cystine residues. Interestingly, the reduction of the
disulfide bonds of the cystine residues led to the formation of
linear polymer chains rather than smaller products. This was
due to the fact that the crosslinker was not present in the backbone
of the nanogel but only on the single chains. The nanogels were
loaded with the anti-inflammatory drug, indometacin, and a
release study under both reducing (102 M dithiothreitol (DTT))
and non-reducing conditions was conducted. The release of
indometacin was complete after 200 h under reducing condi-
tions, while for non-reducing conditions a maximum release of
35% was observed after 80 h.
4. Preclinical and clinical
development/application
Nanogel-based formulations have proven to be useful scaﬀolds
in nanomedicine including drug delivery, anticancer therapy,
imaging, etc., in in vivo animal models, but still many safety
issues have to be overcome before the results can be applied to
clinical practice. Without doubt, cancer is one of the most
challenging and studied applications for hybrid nanogels,
as was discussed in the previous sections and in numerous
reviews.216–219
Table 6 Summary of the most recent and significant studies on core–shell nanogels with controlled drug release
Core Shell Responsiveness Controlled release Ref.
PNIPMAm PNIPMAm-co-aminopropyl
methacrylate-YSA peptide





Poly(aspartic acid) PEG pH Rh-insulin 197
PEG-co-poly(phenylboronic acid) PEG [Glucose] Insulin 198










sive and pH degradable
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Nevertheless, hybrid nanogels were applied not only in
anticancer therapies but also in diﬀerent medical applications
like diabetes,220 skin treatment,221 cosmetics,222 lenses,168 vac-
cines,223 neurosciences,224 lupus,25 etc. Table 7 summarizes the
hybrid nanogels in preclinical and clinical trials.
Kavanov and Vinogradov225 have extensively studied the use
of nanogels for the treatment of neurodegenerative disorders in
order to overcome the rapid clearance of the macromolecules
injected in blood. They have developed cationic nanogels
based on PEG and polyethylenimine for the systemic delivery
of oligonucleotides (ODN) to the central nervous system.226
Further studies proved that by using the core–shell strategy for
modifying the surface of those nanogels with polypeptides
(transferrin or insulin) the permeability of the ODN increased
two-fold.227
So far, the results of using the core–shell strategy in order
to obtain a targeted therapy are promising for further clinical
trials.118 For example, Coll Ferrer et al.228 designed a bio-
compatible nanogel composed of a Dex shell and a lysozyme
core conjugated with an antibody (AntiICAM-1) directed to the
pulmonary endothelium as a dexamethasone carrier to treat
acute pulmonary inflammation in an animal model of LPS-
induced lung injury. In vivo studies demonstrated the therapeutic
efficiency of ICAM-NG-DEX in mice, while when a control nanogel
was used it did not have an anti-inflammatory effect of the
encapsulated drug.
Despite great advances in the development and biological
evaluation of nanogels, only a few examples of clinical trials
have been reported. The most advanced studies are for CHP
nanogels. In 1991 Akiyoshi et al. showed that these hydro-
phobized polysaccharides form monodisperse and colloidally
stable nanogels in water upon self-aggregation229,230 and that
they have a strong binding for hydrophobic guest molecules,231
proteins, and enzymes.232 Since then, CHP nanogels have been
used as drug delivery systems in vivo and in clinical trials, not
only for cancer therapy233–235 but also in treating Alzheimer’s
disorder,236 for bone loss disorder,237 and vaccines.238,239
As an example of CHP preclinical studies, Nochi et al.239
have used CHP nanogels as an intranasal vaccine-delivery
system. In this work, they synthesized a non-ionic CHP nanogel
and a cationic, amino modified, CHP nanogel (cCHP) (Fig. 11),
thereby demonstrating that a neurotoxin BoHc/A administered
Table 7 Hybrid nanogels in preclinical and clinical phase
Phase Hybrid nanogel Application Ref.
Preclinical Plasmonic@NG Cancer therapy 69
Core–shell nanogels Neurodegenerative disorders 224–227
Core–shell nanogels Treatment of acute pulmonary inflammation 228
CHP-W9-peptide Bone loss disorder 237
CHP Vaccines 233, 238 and 239
Clinical CHP Vaccines 234, 235, 240 and 241
Fig. 10 (A) Schematic representation of DOX-loaded Gal-nanogels. (B and C) In vivo studies on HCC-bearing rats after treatment with PBS, free DOX,
m-PPE–DOX, or Gal-PPE–DOX. Adapted from ref. 214 with permission from The Royal Society of Chemistry.
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intranasally with the cCHP nanogel is eﬀectively taken up by
mucosal dendritic cells after its release (Fig. 11b). Moreover, the
hybrid nanogels did not accumulate in the olfactory bulbs or
brain and induced tetanus-toxoid-specific systemic and muco-
sal immune responses.
Clinical trials of CHP nanogels yielded promising results.
In a phase I clinical trial, a CHP–HER2 complex vaccine was
administrated to HER2-expressing cancer patients to evaluate
the safety and immune response to 146HER2.240 The CHP-
HER2 vaccine proved to be safe, well tolerated, and to induce
HER2-specific CD8+ and/or CD4+ T-cell immune response.
In a phase II clinical trial 146HER2-specific antibody responses
following CHP-HER2 vaccination were analyzed.235 The results
indicated that CHP-HER2 induced HER2-specific humoral
responses. Moreover, the antibody titers increased over repeated
vaccinations, and all reached the plateau levels within nine
vaccinations.
Similar results were obtained by Kawabata et al.234,241 when
they evaluated the safety and the humoral immune responses
of CHP-HER2 and CHP-NY-ESO-1 combination vaccines with
the immuno-adjuvant OK-432 administered to therapy-refractory
esophageal cancer patients.
CHP nanogels have shown encouraging results in clinical
trials. However, additional optimization will be necessary for
clinical approval.242
5. Future perspectives and
conclusions
We have discussed here various aspects of hybrid nanogels and
their applicability in nanomedicine. In recent years, it has been
demonstrated that nanotechnology when applied to medicine
can provide superior therapeutics and ways to diagnose diﬀer-
ent diseases. This research area is of such interest that further
developments are occurring almost on a daily basis. The
research on multifunctional hybrid nanogels is mostly focused
on the synthesis of drug delivery systems due to their ability to
eﬃciently encapsulate therapeutics and release them upon an
environmental stimulus. However, the capacity of the hybrid
materials to convert external signals to heat, generate highly
oxidative species, etc., has increased the potential of hybrid
nanogels for combinatorial therapies and theranostics.
Furthermore, due to their size and softness, nanogels are
easily internalized by the cells and show less accumulation in
non-target tissues. Besides these inherent properties of smart
nanogels, hybrid nanogels are very attractive because they
let new sensitivities to be added to the system via a simple
hybridization of the components which allows multiresponsive
materials to be obtained. As we have shown in this review, the
incorporation of new responsivities to smart nanogels widens
the utilization of these systems in several applications such as
Fig. 11 (a) Schematic representation of the hybrid nanogels. (b) Computed tomography images of the drug delivered to the nasal mucosa. (c) Retention
of BoHc/A in the nasal tissues after intranasal immunization. Reprinted with permission from Macmillan Publishers Ltd: Nature Materials from ref. 239,
copyright (2010).




























































































6180 | Chem. Soc. Rev., 2015, 44, 6161--6186 This journal is©The Royal Society of Chemistry 2015
imaging, guided therapy, and hyperthermia. In this way, it is
possible to envision the development of novel materials for
nanomedicine that rely not only on the biological endogenous
signals like acidic pH, reductive potential, enzyme overexpres-
sion, etc., but also on external stimulus for the triggering
of activity. This will enable the preparation of smart nano-
materials with superior targetability and minimized side eﬀects
that exert their therapeutic or diagnostic function only at the
site where the external trigger was applied.
The hybridization of diﬀerent kinds of materials will need
to follow a rational screening that ensures the synergistic combi-
nation of the best properties of both components toward applica-
tions in nanomedicine. This represents a great opportunity for
chemists, material scientists, and biologists to develop new meth-
odologies that allow one to quickly access the properties and
application potential of newly synthesized hybrid nanogels. In
particular, novel biological techniques that provide information
about biodegradability, biological fate, and in vitro and in vivo
therapeutic or diagnostic eﬀects upon irradiation are of great need.
Nevertheless, the application of these new materials in the
industry is still in its first steps and there is an urgent need for
relevant clinical data relating to safety and eﬃcacy of hybrid
nanogels in vivo. In particular, a substantial number of unmet
issues of the plasmonic, magnetic, and carbonaceous nano-
particles, regarding the pharmacodynamics, metabolism, and
pharmacokinetics still need to be assessed before hybrid nanogels
can fully make the transition from bench to bedside. We hope
that by highlighting the latest and more significant studies in the
field, we will inspire the community to develop and perform
studies toward the clinical use of such promising systems.
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